ClinicalTrials.gg
CompletedNCT06126861Updated Mar 15, 2024

The Mass Balance Study of LP-168 in Healthy Subjects

A Phase 1 interventional study of [14C]LP-168 in Clinical Pharmacology, sponsored by Guangzhou Lupeng Pharmaceutical Company LTD.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Guangzhou Lupeng Pharmaceutical Company LTD. (part of Lupeng Pharmaceutical Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi [14C]LP-168 in healthy subjects.

02

Conditions studied

  • Clinical Pharmacology
03

In context

Lead sponsor

Guangzhou Lupeng Pharmaceutical Company LTD. is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • Aged 18-45 (including the boundary value);
  • Body weight over 50 kg, the (BMI) is between 19 and 26 kg/m2 (including the boundary value);
  • Subjects must sign the form voluntarily;
  • Agree to abide the requirements of the study protocol, willing to communicate with the study doctor.

Exclusion criteria

Exclusion Criteria:

  • After a comprehensive physical examination, vital signs, laboratory tests and other examinations are abnormal and have clinical significance;
  • surface antigen or E antigen, virus antibody IgG (Anti-HCV IgG), antigen/antibody combined test (HIV-Ag/Ab) and Treponema pallidum antibody test positive;
  • Subject with abnormalities on ophthalmologic examination (slit lamp, intraocular pressure and fundus photography)
  • Subject who have used any drug that inhibits or induces hepatic drug metabolizing enzymes or transporters during the screening period and within the previous 28 days;
  • Subject who have taken any medication with inhibition gastric acid secretion during the screening period and within the previous 28 days
  • Subject who have taken any anti-gastric acid medication during the screening period and within the previous 28 days
  • Subject who have used any systemic medication during the screening period and within the previous 14 days
  • Subject with a history of any clinically serious illness or disease or condition that, in the opinion of the investigator, may affect the results of the trial
  • Subject with any condition that may affect the absorption of the drug
  • Subject with history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, syndrome, or symptoms of QT prolongation syndrome or family history of these syndrome.
  • Subject with major surgery during the screening period and within the previous 6 months or surgical incisions that have not fully healed
  • Subject with allergies, such as a known history of allergy to two or more substances
  • Subject with hemorrhoids or perianal disease with regular or ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease
  • Subject with habitual constipation or diarrhea
  • Subject with alcohol abuse or regular use of alcohol in the 6 months prior to the screening period
  • Subject with smoking >5 cigarettes per day before the first 3 months of the screening period
  • Subject with drug abuse
  • Subject who are subjected to long-term exposure to radioactive conditions
  • Subject who have difficulty collecting blood or cannot tolerate venipuncture for blood collection
  • Subject with participation in any other clinical trial during the screening period and within the previous 3 months
  • Subject who have been vaccinated during the screening period and within the previous 1 month or who are scheduled to be vaccinated during the trial period
  • Subject with plans to have children or donate sperm during the trial and within 1 year after completion of the trial
  • Subject who had lost or donated up to 400 mL of blood during the screening period and within the previous 3 months, or those who had received a blood transfusion within 1 month;
  • Subject with any factors that the investigator believes make participation in this trial inappropriate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]LP-168

    Using 14C-labeled LP-168 as a marker to investigate the absorption characteristic, as well as to evaluate the metabolism and elimination pathways in healthy subjects

    Drug: [14C]LP-168

Interventions

  • single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state

06

What researchers measure

Primary outcomes

  1. Radioactivity concentration of blood and plasma sample

    Use liquid scintillation counter to evaluate Radioactivity concentration of each sample

    Time frame: Day 1- Day 8

  2. Radioactivity concentration of urine and feces sample

    Use liquid scintillation counter to evaluate Radioactivity concentration of each sample

    Time frame: Day 1- Day 15

  3. Number of metabolites and its proportion in plasma, urine and feces.

    To study the metabolite profiling

    Time frame: Day 1- Day 15

Secondary outcomes

  1. Plasma LP-168/Major Metabolic concentrations

    To determine the plasma concentrations of LP-168/Major Metabolic using LC-MS/MS.

    Time frame: Day 1- Day 8

  2. Treatment emergent adverse events as assessed by CTCAE 5.0

    To evaluate the safety after the study intervention

    Time frame: Day 1- Day 15

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Feb 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Dec 25, 2023
Primary completionActual
Feb 2, 2024
CompletionActual
Mar 13, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06126861
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 25, 2023
Primary completion
Feb 2, 2024
Completion
Mar 13, 2024
Last update
Mar 15, 2024

Study contacts

Liyan Miao, MD
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion